Stent coating

(54) STENT COATING

(75) Inventors: Dachuan Yang, Plymouth, MN (US);

Joel L. Stanslaski, New Hope, MN
(US); Lixiao Wang, Maple Grove, MN
(US); Scott R. Smith, Chaska, MN
(US)

(73) Assignee: SciMed Life Systems, Inc., Maple
Grove, MN (US)

( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 09/883,870

(22) Filed: Jun. 18, 2001

(65) Prior Publication Data

US 2001/0032014 Al Oct. 18, 2001

4,387,024 A 7/1983 Kurihara et al 210/490

4,391,797 A 7/1983 Folkman et al 424/19

4,459,317 A 7/1984 Lambert 427/2

4,487,808 A 12/1984 Lambert 428/423.1

4,492,622 A 1/1985 Kuypers 204/403

4,536,179 A 8/1985 Anderson et al 604/266

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

AU 556 350 Al 10/1983

AU 556 351 Al 10/1986

EP 0 093 094 Al 11/1983

(List continued on next page.)

OTHER PUBLICATIONS

Bartoli et al., 1990 "In Vitro and In Vivo Antitumoral Activity of Free, and Encapsulated Taxol," /. Microencapsulation 7(2): 191-97.

Bruck, 1997, "Interactions of Synthetic and Natural Surfaces with Blood in the Physiological Environment," /. Biomed. Mater. Res. Symposium 8:1-21.

(List continued on next page.)

Primary Examiner—David H. Willse

Assistant Examiner—Suzette J. Jackson

(74) Attorney, Agent, or Firm—Pennie & Edmonds LLP

A stent having a polymeric coating for controllably releasing an included active agent. The polymeric coating includes a blend of a first polymeric material, which if alone, would release the agent at a first, higher rate, and a second polymeric material, which if alone would release the agent at a second, lower rate over a longer time period. One stent coating utilizes a faster releasing hydrophilic polymeric material and a slower releasing hydrophobic material. One stent coating includes a blend of a faster releasing PLA-PEO copolymer and a slower releasing PLA-PCL copolymer. One active agent is Taxol. One use of the Taxol delivering stent is to inhibit restenosis following angioplasty.

34 Claims, 2 Drawing Sheets

U.S. PATENT DOCUMENTS

4,548,844 A 10/1985 Podell et al 428/35

4,642,267 A 2/1987 Creasy et al 428/413

4,666,437 A 5/1987 Lambert 604/265

4,675,361 A 6/1987 Ward, Jr 525/92

4,692,352 A 9/1987 Huddleston 427/208.4

4,705,709 A 11/1987 Vailancourt 428/36

4,721,117 A 1/1988 Mar et al 128/772

4.734.092 A 3/1988 Millerd 604/67

4,748^986 A 6/1988 Morrison et al 128/772

4,768,507 A 9/1988 Fischell et al 128/303 R

4,770,664 A 9/1988 Gogolewski 623/66

4,780,352 A 10/1988 Palumbo 428/138

4,833,014 A 6/1989 Linder et al 428/308.4

4,841,976 A 9/1989 Packard et al 128/657

4,867,173 A 10/1989 Leoni 128/772

4,876,126 A 12/1989 Takemura et al 428/35.7

4,884,579 A 5/1990 Engelson 128/772

4,923,464 A 5/1990 DiPisa, Jr 606/191

4,925,698 A 5/1990 Klausner et al 427/2

4,943,460 A 7/1990 Markle et al 428/36.9

4,959,074 A 9/1990 Halpern et al 623/66

4,964,409 A 10/1990 Tremulis 128/657

4,969,890 A 11/1990 Sugita et al 606/192

4,980,231 A 12/1990 Baker et al 428/36.9

4,994,071 A 2/1991 MacGregor 606/194

5,002,582 A 3/1991 Guire et al 613/66

5,007,928 A 4/1991 Okamura et al 613/6

5,008,363 A 4/1991 Mallon et al 528/49

5,019,096 A 5/1991 Fox, Jr. et al 623/1

5,026,607 A 6/1991 Kiezulas 428/423.7

5,037,656 A 8/1991 Pitt et al 424/443

5,037,677 A 8/1991 Halpern et al 427/338

5,040,543 A 8/1991 Badera et al 128/772

5,049,403 A 9/1991 Larm et al 427/2

5,057,371 A 10/1991 Canty et al 428/411.1

5,066,705 A 11/1991 Wickert 524/457

5,067,489 A 11/1991 Lind 128/772

5,069,217 A 12/1991 Fleischhacker, Jr 128/657

5,069,226 A 12/1991 Yamauchi et al 128/772

5.079.093 A 1/1992 Akashi et al 428/411.1

5,080,683 A 1/1992 Sulc et al 623/66

5,080,924 A 1/1992 Kamel et al 427/2

5,084,315 A 1/1992 Karimi et al 428/36.6

5,091,205 A 2/1992 Fan 427/2

5,092,885 A 3/1992 Yamada et al 623/11

5.102.401 A 4/1992 Lambert et al 604/264

5.102.402 A 4/1992 Dror et al 604/265

5,102,417 A 4/1992 Palmaz 606/195

5,105,010 A 4/1992 Sundararaman et al 564/252

5,107,852 A 4/1992 Davidson et al 128/772

5,128,170 A 7/1992 Matsuda et al 427/2

5,129,890 A 7/1992 Bates et al 604/281

5,160,790 A 11/1992 Elton 428/412

5,211,183 A 5/1993 Wilson 128/772

5,213,111 A 5/1993 Cook et al 128/772

5,217,026 A 6/1993 Stoy et al 128/772

5,222,971 A 6/1993 Willard et al 606/158

5,240,994 A 8/1993 Brink et al 525/54.2

5,241,970 A 9/1993 Johlin, Jr. et al 128/772

5,243,996 A 9/1993 Hall 128/772

5,250,613 A 10/1993 Bergstrom et al 525/54.1

5,266,359 A 11/1993 Spielvogel 427/388.4

5,275.173 A 1/1994 Samson et al 128/772

5,282,823 A 2/1994 Schwartz et al 606/198

5,283,063 A 2/1994 Freeman 424/427

5,290,585 A 3/1994 Elton 427/2

5,304,121 A 4/1994 Sahatjian 604/53

5,304,140 A 4/1994 Kugo et al 604/281

5,324,261 A 6/1994 Amundson et al 604/96

5,370^614 A 12/1994 Amundson et al 604/96

5,380,299 A 1/1995 Fearnot et al 604/265

5,383,928 A 1/1995 Scott et al 623/1

5,419,760 A 5/1995 Narciso, Jr. 604/8

5,423,885 A 6/1995 Williams 623/1

5,443,458 A 8/1995 Eury 604/891.1

5,443,496 A 8/1995 Schwartz et al 623/1

5,447,724 A 9/1995 Helmus et al 424/426

5,449,372 A 9/1995 Schmaltz et al 606/198

5,449,382 A 9/1995 Dayton 623/1

5,464,650 A 11/1995 Berg et al 427/2.3

5,470,829 A 11/1995 Prisell et al 514/12

5,476,909 A 12/1995 Kim et al 525/408

5,512,055 A 4/1996 Domb et al 604/265

5,514,154 A 5/1996 Lau et al 606/195

5,527,337 A 6/1996 Stack et al 606/198

5,545,208 A 8/1996 Wolff et al 623/1

5,548,035 A 8/1996 Kim et al 525/408

5,562,922 A 10/1996 Lambert 424/486

5,569,463 A 10/1996 Helmus et al 424/426

5,576,072 A 11/1996 Hostettler et al 427/532

5,578,075 A 11/1996 Dayton 623/1

5,591,227 A 1/1997 Dinh et al 623/1

5,605,696 A 2/1997 Eury et al 424/423

5,609,629 A 3/1997 Fearnot et al 623/1

5,616,608 A 4/1997 Kinsella et al 514/449

5,620,738 A 4/1997 Fan et al 427/2.3

5,624,411 A 4/1997 Tuch 604/265

5,626,862 A 5/1997 Brem et al 424/426

5,637,113 A 6/1997 Tartaglia et al 623/1

5^651,986 A 7/1997 Brem et al 424/484

5,674,192 A 10/1997 Sahatjian et al 604/28

5.674.241 A 10/1997 Bley et al 606/198

5.674.242 A 10/1997 Phan et al 606/198

5,679,400 A 10/1997 Tuch 427/2.14

5,697,967 A 12/1997 Dinh et al 623/1

5,700,286 A 12/1997 Tartaglia et al 623/1

5,702,754 A 12/1997 Zhong 427/2.12

5,709,874 A 1/1998 Hanson et al 424/423

5,712,326 A 1/1998 Jones et al 523/105

5,716,981 A 2/1998 Hunter et al 514/449

5,733,925 A 3/1998 Kunz et al 514/449

5,739,237 A 4/1998 Russell et al 526/277

5,755,769 A 5/1998 Richard et al 623/11

5,776,184 A 7/1998 Tuch 623/1

5,799,732 A 9/1998 Gonzalez et al 606/198

5,837,008 A 11/1998 Berg et al 623/1

5,902,332 A 5/1999 Schatz 623/1.16

5,957,975 A 9/1999 Lafont et al 623/1.38

5,972,027 A 10/1999 Johnson 623/1.39

5,977,163 A 11/1999 Li et al 514/449

6.099.561 A 8/2000 Alt 623/1.44

6.099.562 A 8/2000 Ding et al 623/1.46

6.099.563 A 8/2000 Zhong 623/1.46

6,120,536 A 9/2000 Ding et al 623/1.43

6,231,600 Bl * 5/2001 Zhong 623/1.42

6,258,121 Bl * 7/2001 Yang et al 623/1.46

6,287,285 Bl * 9/2001 Michal et al 604/264

6,299,604 Bl * 10/2001 Ragheb et al 604/265

6,306,166 Bl * 10/2001 Barry et al 623/1.46

6,335,029 Bl * 1/2002 Kamath et al 424/423

6,369,039 Bl * 4/2002 Palasis et al 514/44

FOREIGN PATENT DOCUMENTS

EP 0 106 004 Al 4/1984

EP 0 166 988 A2 1/1986

EP 0 274 846 Bl 7/1988

EP 0 294 905 Al 12/1988

EP 0 389 632 Al 10/1990

EP 0 395 098 Al 10/1990

EP 0 407 965 Al 1/1991

EP 0 439 908 Al 8/1991

OTHER PUBLICATIONS

Cohn et al, 1988, "Biodegradable PEO/PLABlcok Copolymers," Journal of Biomedical Materials Research 22(11):993-1009.

Cox et al., 1992, "Effect of Local Delivery of Heparin and Methotrexate on Neointimal Proliferation in Stented Porcine Coronary Arteries," Coronary Artery Disease 3(3):237-248. Cox et al., 1991, "Local Delivery of Heparin and Methotrexate Fails to Inhibit In Vivo Smooth Muscle Cell Proliferation," Supplement to Circulation Abstracts From the 64th Scientific Sessions, 84(4):II-71, Abstract No. 0284. Dev et al., 1993, "Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane Coated Removable Nitinol Stent— Comparative Study of 2 Drugs," Circulation Abstracts From the 66th Scientific Sessions, 88(4) (Part 2):I-3, Abstract No. 1657.

Esquivel et al., 1984, "Reduced Thrombogenic Characteristics of Expanded Polytetrafluorethylene and Polyurethane Arterial Grafts After Heparin Bonding," Surgery, pp. 102-107.

Guyton et al., 1980, "Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin," Circulation Research 46(5): 625-634.

Jampel et al., In Vitro Release of Hydrophobic Drugs From Polyanhydride Disks, Ophthalmic Surgery, dated prior to Jan. 8, 1991.

Kawahito et al., 1994, "Heparin Coated Percutaneous Cardiopulmonary Support for the Treatment of Circulatory Collapse After Cardiac Surgery," ASAIO Journal 40(4):972-976.

Kishida et al., 1994, "Immobilization of Human Thrombomodulin onto BiomsAeimls," ASAIO Journal, Slide Forum— Materials 4, pp. M840-M845.

Lambert et al., 1993, "A New Method For Arterial Drug Delivery Via Removable Stent," JACC 21(2):483A, Abstract No. 834-2.

Lambert et al., 1993, "Localized Arterial Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics and Bioactivity of Forskolin," Circulation Abstracts from the 66th Scientific Sessions, 88(4)(Part 2):I-3, Abstract No. 1659.

Lindhardt et al., 19XX, "Differential Anticoagulant Activity of Heparin Fragments Prepared Using Microbial Heparinase," The Journal of Biological Chemistry 257(13):7310-7313.

Miyama et al., 1977, "A New Antigrhombogenic Heparinized Polymer,"/. Biomed. Mater. Res. 11:251-265.

Moses et al., 1999, Inhibitors onAngiogenesis, Review, The Children's Hospital Medical Center, Boston, MA, dated prior to Jan. 8, 1999.

Nichols et al., 1984, "Effect of Heparin Bonding on Catheter-induced Fibrin Formation and Platelet Activation," Circulation 70(5):843-850.

Pitt et al., 1980, "The Design of Controlled Drug Delivery Systems Based on Biodegradable Polymers," Progress in Contraceptive Delivery Systems, MTP Press, Lancaster 1:17-18.

Sheppeck et al., 1991, "Examination of the Roles of Glycoprotein lb and Glycoprotein Iib/IIIa in Platelet Deposition on an Artificial Surface Using Clinical Antiplatelet Agents and Monoclonal Antibody Blockage," Blood 78(3):673-680.

Tang et al., 1993, "Regression of Collagen-Induced Arthritis with Taxol, A Microtubule Stabilizer," Arthritis Rheum. 36(9)(Suppl.):42.

"A Powerful Case for LOPID," Parke-Davis, dated prior to Jan. 8, 1999.

Whitborne, Presentation at the 2nd International Coronary Stenting Summit (Mar. 1-2, 1991).

Wilson, Internet Article dated Jan. 21, 1991, "Thromboresistant Plastic Coarding Treatment," Research Partners, Inc., 2 pages.

* cited by examiner